More tools:
Markets
·
Screener
·
Research
·
Chat
Polaryx Therapeutics, Inc. Common Stock (PLYX) Financial Statements
Polaryx Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01ZPFWWC1
XNAS · usd
2.03
▲ 0.01 (0.50%)
As of 2026-09-09
1M
6M
1Y
Valuation
Market Cap
$101.2M
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
2.02
Day's Range
1.97 – 2.04
52-Week Range
1.85 – 49.50
Volume
14.1K
Avg Volume
100.7K
Share Statistics
Shares Outstanding
49.8M
Employees
—
Exchange
XNAS
Listed
2026-02-02
Share count as of July 31, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about Polaryx Therapeutics, Inc. Common Stock (PLYX)
What is Polaryx Therapeutics, Inc. Common Stock's Market Cap?
Polaryx Therapeutics, Inc. Common Stock's Market Cap is $101.2M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Operating expenses:
Research and development expenses
719.0
679.0
General and administrative expenses
661.0
1,279.0
Total operating expenses
1,380.0
1,958.0
Operating loss
(1,380.0)
(1,958.0)
Other expense – direct listing offering costs
0.0
(586.0)
Net loss and comprehensive loss
(1,380.0)
(2,544.0)
Net loss per share – basic
(0.03)
(0.05)
Net loss per share – diluted
(0.03)
(0.05)